Company / R&D Expense
Catalyst Pharmaceuticals Partners, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$12.7M
FY2025
5-year range
$12.6M / $93.2M
FY2021-FY2025
Trend
+0.5%
vs FY2024
Sector context
#204 of 210
Health Care
What the data says
Among 210 Health Care companies, Catalyst Pharmaceuticals Partners, Inc. is in the bottom 3% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $11M in FY2016 to $93M in FY2023.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -5.1%.
Declined from $93M to $13M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -13.7%
- 5-Year CAGR
- -5.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 210This company $12.7M Sector average $644.1M
▼
-98.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.1%, indicating a declining trend.
- In FY2025, r&d expense increased 0.5% year-over-year.
- Ranks #204 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.7M | +0.5% |
| FY2024 | $12.6M | -86.4% |
| FY2023 | $93.2M | +370.7% |
| FY2022 | $19.8M | +16.8% |
| FY2021 | $16.9M | +2.7% |
| FY2020 | $16.5M | -12.5% |
| FY2019 | $18.8M | -5.4% |
| FY2018 | $19.9M | +68.8% |
| FY2017 | $11.8M | +3.8% |
| FY2016 | $11.4M | -3.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026